Pharma Focus America
ThermoFisher Scientific - Go beyond the catalog

WuXi Biologics Invests US$1.4 billion in Singapore for a New CRDMO Center

Introduction:

WuXi Biologics will invest US$1.4 billion over ten years in a new CRDMO facility in Singapore.

Features:

The company will increase its capacity and capabilities for large-scale drug substance and drug product (DS/DP) manufacture as part of the plan.

Additionally, it will construct a new bio-manufacturing plant that will add 120,000 litres of capacity by 2026 and hire 1,500 specialized workers for manufacture, research, and development.

The facility will also assist WuXi Biologics' Global Dual Sourcing Strategy which aims to minimize risks by ensuring that customer projects can be completed at several locations around the world.

Specifications:

NameWuXi Biologics
TypeExpansion
BudgetUS$1.4 billion
Year2026
Sartorius Lab Balance CleaningFestival of Biologics San Diego 2024Equinix accelerated medical research...World Vaccine Congress Europe 2024World Orphan Drug Congress 2024World Vaccine Congress Washington 2024Future Labs Live USA 2024Interphex 2024Pharma USA 2024